Adult Neurology Clinical Trials
|I5Q-MC-B004||preventive Treatment of mIgraine: oUtcoMes for Patients in real-world Healthcare systems (TRIUMPH)||The purpose of this study is to collect information about treatment patterns, effects, and outcomes in patients with migraine who are switching or initiating a pharmacologic treatment for migraine prevention.
||A Randomized, Double- blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib
||The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.
The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).
The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.
|COMB157G23101||An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from dimethyl fumarate or fingolimod to ofatumumab||The purpose of the study is to complement the ofatumumab pivotal Phase 3
program by exploring outcomes of patients transitioning from commonly used
oral therapies, dimethyl fumarate (DMF) or fingolimod, to ofatumumab due to
breakthrough disease (defined as relapse, Gd+, or new/enlarging T2 lesions)
|COMB157GUS12||A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab||To assess whether participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once every 4 weeks (q4) can mount an adequate immune response to inactivated influenza vaccine as measured by humoral responses compared to participants on an iDMT.|